(Q37176371)

18 August 2017

1 reference

title

Gastrointestinal stromal tumors: key to diagnosis and choice of therapy (English)

1 reference

18 August 2017

0 references

1

Piotr Rutkowski

1 reference

18 August 2017

2

Maria Debiec-Rychter

1 reference

18 August 2017

3

Wlodzimierz Ruka

1 reference

18 August 2017

1 January 2008

1 reference

Molecular Diagnosis and Therapy

18 August 2017

1 reference

18 August 2017

12

1 reference

18 August 2017

3

1 reference

18 August 2017

131-143

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03256278

18 August 2017

0 references

cites work

Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Gastrointestinal stromal tumor (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Diagnosis of gastrointestinal stromal tumors: a consensus approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Gastrointestinal stromal tumors: pathology and prognosis at different sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Analysis of prognostic and immunohistochemical factors in gastrointestinal stromal tumors with malignant potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Clinicopathological and immunohistochemical analysis of gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Expression and prognostic role of molecular markers in 99 KIT-positive gastric stromal tumors in Taiwanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Biology of gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Allelic loss of 14q and 22q, NF2 mutation, and genetic instability occur independently of c-kit mutation in gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

High Prognostic Value of p16INK4 Alterations in Gastrointestinal Stromal Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

The role of KIT in the management of patients with gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Rectal gastrointestinal stromal tumors associated with a novel germline KIT mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Familial gastrointestinal stromal tumours with germline mutation of the KIT gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Carney triad: case report and molecular analysis of gastric tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Multiple gastrointestinal stromal tumors of the ileum and neurofibromatosis type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

High incidence of microscopic gastrointestinal stromal tumors in the stomach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

The effect of surgery and grade on outcome of gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Optimizing diagnosis, staging, and management of gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Clinical management of gastrointestinal stromal tumors: before and after STI-571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

New developments in gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

ARG tyrosine kinase activity is inhibited by STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Gastrointestinal stromal tumors (GIST)--current concepts of surgical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: report of a case

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256278

Multicentric sporadic gastrointestinal stromal tumors (GISTs) of the stomach with distinct clonal origin: differential diagnosis to familial and syndromal GIST variants and peritoneal metastasis

21 January 2018

1 reference

12 December 2020

Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation

1 reference

12 December 2020

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

1 reference

12 December 2020

Gastrointestinal stromal tumors--value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas

1 reference

12 December 2020

Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors

1 reference

12 December 2020

Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs)

1 reference

12 December 2020

NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

1 reference

12 December 2020

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors

1 reference

12 December 2020

A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors

1 reference

12 December 2020

Cytogenetic and morphologic characteristics of gastrointestinal stromal tumors. Recurrent rearrangement of chromosome 1 and losses of chromosomes 14 and 22 as common anomalies

1 reference

12 December 2020

Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours

1 reference

12 December 2020

Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.

1 reference

12 December 2020

Predicting prognosis of gastrointestinal smooth muscle tumors. Role of clinical and histologic evaluation, flow cytometry, and image cytometry.

1 reference

12 December 2020

Sunitinib in the management of gastrointestinal stromal tumours (GISTs).

1 reference

12 December 2020

Diagnosis of gastrointestinal stromal tumors: A consensus approach

1 reference

12 December 2020

DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance

1 reference

12 December 2020

Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas

1 reference

12 December 2020

Analysis of KIT mutation and protein expression in fine needle aspirates of gastrointestinal stromal/smooth muscle tumors

1 reference

12 December 2020

Surgical resection of gastrointestinal stromal tumors after treatment with imatinib

1 reference

12 December 2020

Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors

1 reference

12 December 2020

Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene

1 reference

12 December 2020

Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors

1 reference

12 December 2020

Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal

1 reference

12 December 2020

Large gastrointestinal stromal tumor presenting as an ovarian tumor. A case report

1 reference

12 December 2020

Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases

1 reference

12 December 2020

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer

1 reference

12 December 2020

Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis

1 reference

12 December 2020

Gastrointestinal Stromal Tumors, Intramural Leiomyomas, and Leiomyosarcomas in the Duodenum: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 167 Cases

1 reference

12 December 2020

KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors

1 reference

12 December 2020

Gastrointestinal stromal tumors. A review of characteristics morphologic, immunohistochemical, and molecular genetic features

1 reference

12 December 2020

DNA ploidy and proliferative index in gastrointestinal stromal tumors

1 reference

12 December 2020

Multiple familial gastrointestinal autonomic nerve tumors and small intestinal neuronal dysplasia

1 reference

12 December 2020

An oncogenetic tree model in gastrointestinal stromal tumours (GISTs) identifies different pathways of cytogenetic evolution with prognostic implications

1 reference

12 December 2020

Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours

1 reference

12 December 2020

Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors

1 reference

12 December 2020

Resistance to c-KIT kinase inhibitors conferred by V654A mutation

1 reference

12 December 2020

A Flow Cytometric, Clinical, and Histological Study of Stromal Neoplasms of the Gastrointestinal Tract

1 reference

12 December 2020

Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. gastrointestinal stromal tumors

1 reference

12 December 2020

Gastrointestinal stromal tumors with prominent signet-ring cell features

1 reference

12 December 2020

Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors

1 reference

12 December 2020

Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT)

1 reference

12 December 2020

Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients

1 reference

12 December 2020

KIT activation is a ubiquitous feature of gastrointestinal stromal tumors

1 reference

12 December 2020

Cell-type- and tumour-type-related patterns of bcl-2 reactivity in mesenchymal cells and soft tissue tumours

1 reference

12 December 2020

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

1 reference

12 December 2020

Risk Criteria and Prognostic Factors for Predicting Recurrences After Resection of Primary Gastrointestinal Stromal Tumor

1 reference

12 December 2020

Array CGH analysis in primary gastrointestinal stromal tumors: Cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status

1 reference

12 December 2020

Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad

1 reference

12 December 2020

Immunohistologic characterization of gastrointestinal stromal tumors: a study of 82 cases compared with 11 cases of leiomyomas

1 reference

12 December 2020

Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor

1 reference

12 December 2020

[Gastrointestinal stromal tumors localized in small intestine and diagnosed preoperatively as gynecological neoplasms]

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03256278

1 reference

18 August 2017

1 reference

PubMed ID

18510377